{"id":"e92ad0e8f065","type":"article","url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","title":"Empagliflozine bij hartfalen: cardiovasculaire en renale uitkomsten — NEJM EMPEROR-Reduced","title_en":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfmref","hfpef","hfref","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2022190","source_url":"https://doi.org/10.1056/NEJMoa2022190","authors":["Milton Packer","Stefan D Anker","Javed Butler","Gerasimos Filippatos","Stuart J Pocock","Peter Carson","James Januzzi","Subodh Verma","Hiroyuki Tsutsui","Martina Brueckmann","Waheed Jamal","Karen Kimura","Janet Schnee","Cordula Zeller","Daniel Cotton","Edimar Bocchi","Michael Böhm","Dong-Ju Choi","Vijay Chopra","Eduardo Chuquiure","Nadia Giannetti","Stefan Janssens","Jian Zhang","Jose R Gonzalez Juanatey","Sanjay Kaul","Hans-Peter Brunner-La Rocca","Bela Merkely","Stephen J Nicholls","Sergio Perrone","Ileana Pina","Piotr Ponikowski","Naveed Sattar","Michele Senni","Marie-France Seronde","Jindrich Spinar","Iain Squire","Stefano Taddei","Christoph Wanner","Faiez Zannad"],"significance":10,"published":"2020-10-08","source_date":"2020-10-08","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"The EMPEROR-Reduced trial showed that empagliflozin significantly reduced the composite of cardiovascular death or heart failure hospitalization in patients with HFrEF, regardless of diabetes status. Together with DAPA-HF, this confirmed the class effect of SGLT2 inhibitors in heart failure and supported their addition to guideline-directed therapy.","created":"2026-07-03T10:28:49Z","updated":"2026-07-03T18:38:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Landmark NEJM EMPEROR-Reduced trial die aantoonde dat empagliflozine cardiovasculaire dood en HF-hospitalisatie significant vermindert bij HFrEF, ongeacht diabetes. Bevestigt het SGLT2-remmer klasse-effect voor hartfalen samen met DAPA-HF.","abstract_original":"BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS: In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS: During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS: Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.)."}